Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alemtuzumab (Millennium/ILEX).

F J Dumont1

  • 1Merck Research Laboratories, Department of Immunology, Rahway, NJ 07065, USA. frances_dumont@merck.com

Current Opinion in Investigational Drugs (London, England : 2000)
|August 31, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BMS-188667 (Bristol-Myers Squibb).

IDrugs : the investigational drugs journal·2005
Same author

Everolimus. Novartis.

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Treatment of transplant rejection: are the traditional immunosuppressants good enough?

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

FK506, an immunosuppressant targeting calcineurin function.

Current medicinal chemistry·2000
Same author

Hypothemycin inhibits the proliferative response and modulates the production of cytokines during T cell activation.

Immunopharmacology·1999
Same author

C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study.

Bioorganic & medicinal chemistry letters·1999
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Alemtuzumab, a targeted therapy, shows promise for treating chronic lymphocytic leukemia (CLL). Regulatory agencies are reviewing its potential for accelerated approval, indicating significant therapeutic interest.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Alemtuzumab is a lymphocyte-depleting humanized monoclonal antibody.
  • It is being developed for chronic lymphocytic leukemia (CLL) and other conditions like graft-versus-host disease and multiple sclerosis.

Purpose of the Study:

  • To investigate the therapeutic potential of alemtuzumab in various medical conditions.
  • To gain regulatory approval for alemtuzumab in treating chronic lymphocytic leukemia (CLL).

Main Methods:

  • Filing of Biologics License Application (BLA) with the FDA and Marketing Authorization Application (MAA) with EMEA.
  • Review by the FDA's Oncologic Drugs Advisory Committee.
  • Clinical trials for various indications including CLL, vasculitis, multiple sclerosis, and organ transplantation.

Related Experiment Videos

Main Results:

  • FDA Oncologic Drugs Advisory Committee recommended accelerated approval for alemtuzumab in specific CLL patient populations.
  • MAA accepted by EMEA for centralized approval procedure.

Conclusions:

  • Alemtuzumab demonstrates potential as a treatment for chronic lymphocytic leukemia (CLL).
  • Regulatory review processes are underway in both the US and Europe.